

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

January 2024

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white and grey wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 January 2024	3
Section H changes to Part II	6
Index	14

Summary of decisions

EFFECTIVE 1 JANUARY 2024

- Abacavir sulphate (Ziagen) oral liq 20 mg per ml, 240 ml – to be delisted 1 July 2024
- Allopurinol (DP-Allopurinol) tab 100 mg and 300 mg – to be delisted 1 June 2024
- Allopurinol (Ipca-Allopurinol) tab 100 mg and 300 mg – new listing and addition of PSS
- Amiloride hydrochloride (Biomed) oral liq 1 mg per ml, 25 ml – price increase
- Aripiprazole (Abilify Maintena) inj 300 mg vial and 400 mg vial – new listing
- Aspirin (Ethics Aspirin EC) tab 100 mg – price decrease and addition of PSS
- Budesonide (SteroClear) nasal spray 50 mcg per dose and 100 mcg per dose – price increase
- Bupivacaine hydrochloride with fentanyl (Biomed) inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe – price increase
- Caffeine citrate (Biomed) oral liq 20 mg per ml (caffeine 10 mg per ml), 25 ml and inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – price increase
- Chlorothiazide (Biomed) oral liq 50 mg per ml, 25 ml – price increase
- Clarithromycin (Klacid) tab 250 mg and 500 mg – extended HSS expiry date
- Colecalciferol (Vit.D3) cap 1.25 mg (50,000 iu) – price increase and addition of PSS
- Dexamethasone (Biomed) oral liq 1 mg per ml, 25 ml – price increase
- Dexamfetamine sulfate (Aspen and PSM) tab 5 mg – to be delisted 1 June 2024
- Dexamfetamine sulfate (Noumed Dexamfetamine) tab 5 mg – new listing and addition of PSS
- Dexamfetamine sulfate (PSM) tab 5 mg – removal of PSS
- Diltiazem hydrochloride (Cardizem CD) cap long-acting 180 mg and 240 mg – extended HSS expiry date
- Donepezil hydrochloride (Donepezil-Rex) tab 5 mg and 10 mg – to be delisted 1 June 2024
- Donepezil hydrochloride (Ipca-Donepezil) tab 5 mg and 10 mg – new listing and addition of PSS
- Ephedrine (Ephedrine Juno) inj 3 mg per ml, 10 ml syringe – new listing and addition of PSS
- Febuxostat (Febuxostat (Teva)) tab 80 mg and 120 mg – new listing and addition of PSS
- Febuxostat (Febuxostat multichem) tab 80 mg and 120 mg – to be delisted 1 June 2024

Summary of decisions – effective 1 January 2024 (continued)

- Fentanyl (Biomed) inj 20 mcg per ml, 50 ml syringe, 5 inj pack – new listing
- Fentanyl (Biomed) inj 20 mcg per ml, 50 ml syringe, 1 inj pack – to be delisted 1 June 2024
- Folic acid (Biomed) oral liq 50 mcg per ml, 25 ml – price increase
- Folic acid (Folic Acid Viatris) tab 5 mg – extended HSS expiry date
- Gabapentin (Nupentin) cap 100 mg, 300 mg and 400 mg – extended HSS expiry date
- Gemcitabine hydrochloride (DBL Gemcitabine) inj 43.3 mg per ml (equivalent to 38 mg per ml gemcitabine), 26.3 ml vial – new listing, amended chemical name and addition of PSS
- Gemcitabine hydrochloride (Gemcitabine Ebewe) inj 10 mg per ml, 100 ml vial – to be delisted 1 June 2024
- Glucose [Dextrose] (Fresenius Kabi) inj 5%, 100 ml, 250 ml, 500 ml and 1,000 ml bag – price increase
- Hydrocortisone and paraffin liquid and lanolin (DP Lotn HC) lotn 1% with paraffin liquid 15.9% and lanolin 0.6%, 250 ml – price increase and addition of PSS
- Influenza vaccine inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) (Afluria Quad Junior (2023 Formulation)) and inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) (Afluria Quad (2023 formulation)) – amended restriction criteria and to be delisted 1 February 2024
- Ketamine (Biomed) inj 1 mg per ml, 100 ml bag and 10 mg per ml, 10 ml syringe – price increase
- Lapatinib (Tykerb) tab 250 mg – to be delisted 1 March 2024
- Letrozole (Letrole) tab 2.5 mg – new Pharmacode listing
- Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride (Topicaine) soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – price increase
- Magnesium sulphate (Inresa) inj 2 mmol per ml, 10 ml ampoule – new listing
- Magnesium sulphate (Martindale) inj 2 mmol per ml, 5 ml ampoule – price increase and addition of PSS
- Meropenem (Meropenem-AFT) inj 500 mg vial and 1 g vial – price decrease and addition of PSS
- Metformin hydrochloride (Metformin Viatris) tab immediate-release 500 mg and 850 mg – extended HSS expiry date
- Metoprolol tartrate (IPCA-Metoprolol) tab 50 mg and 100 mg – extended HSS expiry date
- Nifedipine (Mylan (24 hr release)) tab long-acting 30 mg – revoke delisting

Summary of decisions – effective 1 January 2024 (continued)

- Oestradiol (Estradot) patch 25 mcg per day, 50 mcg per day, 75 mcg per day and 100 mcg per day – price increase
- Paraffin (EVARA White Soft Paraffin) white soft, 450 g – new listing, addition of PSS and note
- Paraffin (healthE) white soft, 450 g – to be delisted 1 June 2024
- Pegylated interferon alfa-2a (Pegasys) inj 180 mcg prefilled syringe – price increase
- Phenobarbitone (Noumed Phenobarbitone) tab 15 mg – to be delisted 1 January 2024
- Phenobarbitone (PSM) tab 15 mg – revoke delisting
- Potassium citrate (Biomed) oral liq 3 mmol per ml, 200 ml – price increase
- Propranolol tab 10 mg (Drofate) and tab 40 mg (IPCA-Propranolol) – extended HSS expiry date
- Sodium bicarbonate (Biomed) inj 8.4%, 50 ml vial and 100 ml vial – price increase
- Sodium chloride (Biomed) inj 23.4% (4 mmol/l), 20 ml ampoule – price increase
- Sodium chloride (Fresenius Kabi) irrigation soln 0.9%, 250 ml bottle – price increase
- Sodium dihydrogen phosphate [Sodium acid phosphate] (Biomed) inj 1 mmol per ml, 20 ml ampoule – price increase
- Spironolactone (Biomed) oral liq 5 mg per ml, 25 ml – price increase
- Sucrose (Biomed) oral liq 25%, 25 ml – price increase
- Sumatriptan (Sumagran) tab 50 mg and 100 mg – extended HSS expiry date
- Teriparatide (Forteo) inj 250 mcg per ml, 2.4 ml – to be delisted 1 June 2024
- Teriparatide (Teriparatide – Teva) inj 250 mcg per ml, 2.4 ml – amended presentation description, new listing and addition of PSS
- Water (Fresenius Kabi) irrigation soln, 250 ml bottle – price increase

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 January 2024

ALIMENTARY TRACT AND METABOLISM

11	METFORMIN HYDROCHLORIDE (extended HSS expiry date) Tab immediate-release 500 mg – 1% DV Mar-23 to 2024 2027	14.74	1,000	Metformin Viatris
	Tab immediate-release 850 mg – 1% DV Aug-23 to 2024 2027	11.28	500	Metformin Viatris
24	MAGNESIUM SULPHATE († price and addition of PSS) Inj 2 mmol per ml, 5 ml ampoule – 5% DV Jun-24 to 2026	37.53	10	Martindale
24	MAGNESIUM SULPHATE (new listing) Inj 2 mmol per ml, 10 ml ampoule.....	75.06	10	Inresa
27	COLECALCIFEROL († price and addition of PSS) Cap 1.25 mg (50,000 iu) – 5% DV Jun-24 to 2026	3.65	12	Vit.D3

BLOOD AND BLOOD FORMING ORGANS

30	FOLIC ACID (extended HSS expiry date) Tab 5 mg – 1% DV Mar-23 to 2024 2027	5.82	100	Folic Acid Viatris
30	FOLIC ACID († price) Oral liq 50 mcg per ml	30.26	25 ml	Biomed
36	ASPIRIN († price and addition of PSS) Tab 100 mg – 5% DV Jun-24 to 2026	12.65	990	Ethics Aspirin EC
41	SODIUM BICARBONATE († price) Inj 8.4%, 50 ml vial	23.52	1	Biomed
	Inj 8.4%, 100 ml vial	24.10	1	Biomed
41	SODIUM CHLORIDE († price) Inj 23.4% (4 mmol/ml), 20 ml ampoule.....	38.25	5	Biomed
41	SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE] († price) Inj 1 mmol per ml, 20 ml ampoule.....	56.30	5	Biomed
40	GLUCOSE [DEXTRROSE] († price) Inj 5%, 1,000 ml bag	52.00	10	Fresenius Kabi
	Inj 5%, 100 ml bag	95.00	50	Fresenius Kabi
	Inj 5%, 250 ml bag	61.50	30	Fresenius Kabi
	Inj 5%, 500 ml bag	66.00	20	Fresenius Kabi

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2024 (continued)

CARDIOVASCULAR SYSTEM

47	METOPROLOL TARTRATE (extended HSS expiry date) Tab 50 mg – 1% DV Mar-22 to 2024 2027 5.66 Tab 100 mg – 1% DV Mar-22 to 2024 2027 7.55	100 60	IPCA-Metoprolol IPCA-Metoprolol
48	PROPRANOLOL (extended HSS expiry date) Tab 10 mg – 1% DV Mar-22 to 2024 2027 7.04 Tab 40 mg – 1% DV Mar-22 to 2024 2027 8.75	100 100	Drofate IPCA-Propranolol
48	NIFEDIPINE (revoke delisting) Tab long-acting 30 mg 34.10 Note—Mylan (24 hr release) Tab long-acting 30 mg to be delisted 1 February 2024	100	Mylan (24 hr release)
50	AMILORIDE HYDROCHLORIDE (↑ price) Oral liq 1 mg per ml 33.71	25 ml	Biomed
50	SPIRONOLACTONE (↑ price) Oral liq 5 mg per ml 34.65	25 ml	Biomed
50	CHLOROTHIAZIDE (↑ price) Oral liq 50 mg per ml 29.21	25 ml	Biomed
53	DILTIAZEM HYDROCHLORIDE (extended HSS expiry date) Cap long-acting 180 mg – 1% DV Mar-22 to 2024 2027 7.00 Cap long-acting 240 mg – 1% DV Mar-22 to 2024 2027 9.30	30 30	Cardizem CD Cardizem CD
54	EPHEDRINE (new listing and addition of PSS) Inj 3 mg per ml, 10 ml syringe – 5% DV Jun-24 to 2026 142.00	10	Ephedrine Juno

DERMATOLOGICALS

69	PARAFFIN (new listing, addition of PSS and note) White soft, – 5% DV Jun-24 to 2026 4.74	450 g	EVARA White Soft Paraffin
Note: DV limit applies to the pack sizes of 500 g or less and greater than 30 g.			
Note – healthE paraffin white soft, 450 g to be delisted from 1 June 2024			
70	HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN (↑ price and addition of PSS) Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – 5% DV Jun-24 to 2026 12.83	250 ml	DP Lotn HC

GENITO-URINARY SYSTEM

76	POTASSIUM CITRATE (↑ price) → Oral liq 3 mmol per ml 35.70	200 ml	Biomed
----	---	--------	--------

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2024 (continued)

HORMONE PREPARATIONS

79	DEXAMETHASONE (↑ price) Oral liq 1 mg per ml	52.80	25 ml	Biomed
80	OESTRADIOL (↑ price) Patch 25 mcg per day..... Patch 50 mcg per day..... Patch 75 mcg per day..... Patch 100 mcg per day.....	14.50 14.50 14.50 14.50	8 8 8 8	Estradot Estradot Estradot Estradot

INFECTIONS

89	MEROPENEM (↓ price and addition of PSS) → Inj 500 mg vial – 5% DV Jun-24 to 2026	33.48	10	Meropenem-AFT
	→ Inj 1 g vial – 5% DV Jun-24 to 2026	44.97	10	Meropenem-AFT
91	CLARITHROMYCIN (extended HSS expiry date) → Tab 250 mg – 1% DV Feb-22 to 2024 2027	8.53	14	Klacid
	→ Tab 500 mg – 1% DV Feb-22 to 2024 2027	14.58	14	Klacid
102	ABACAVIR SULPHATE (delisting) → Oral liq 20 mg per ml	256.31	240 ml	Ziagen
	Note – Ziagen oral liq 20 mg per ml, 240 ml to be delisted from 1 July 2024			
109	PEGYLATED INTERFERON ALFA-2A (↑ price) → Inj 180 mcg prefilled syringe.....	748.50	4	Pegasys

MUSCULOSKELETAL SYSTEM

115	ALLOPURINOL (new listing and addition of PSS) Tab 100 mg – 5% DV Jun-24 to 2026	17.99	1000	Ipca-Allopurinol
	Tab 300 mg – 5% DV Jun-24 to 2026	22.50	500	Ipca-Allopurinol
	Note – DP-Allopurinol tab 100 mg and 300 mg to be delisted from 1 June 2024			
115	FEBUXOSTAT (new listing and addition of PSS) → Tab 80 mg – 5% DV Jun-24 to 2026	4.73	28	Febuxostat (Teva)
	→ Tab 120 mg – 5% DV Jun-24 to 2026	11.78	28	Febuxostat (Teva)
	Note – Febuxostat multichem tab 80 mg and 120 mg to be delisted from 1 June 2024			
141	TERIPARATIDE (amended presentation description, new listing and addition of PSS) → Inj 250 mcg per ml, 2.4 ml cartridge – 5% DV Jun-24 to 2025	195.00	1	Teriparatide - Teva
	Note – Forteo inj 250 mcg per ml, 2.4 ml to be delisted from 1 June 2024			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2024 (continued)

NERVOUS SYSTEM

120	KETAMINE († price)			
	Inj 1 mg per ml, 100 ml bag.....	141.75	5	Biomed
	Inj 10 mg per ml, 10 ml syringe	73.50	5	Biomed
122	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL († price)			
	Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe.....	54.60	5	Biomed
122	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE († price)			
	Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe	19.70	1	Topicaïne
124	SUCROSE († price)			
	Oral liq 25%.....	13.91	25 ml	Biomed
125	FENTANYL (new listing)			
	Inj 20 mcg per ml, 50 ml syringe	136.50	5	Biomed
	Note – Biomed inj 20 mcg per ml, 50 ml syringe, 1 inj pack to be delisted from 1 June 2024			
129	PHENOBARBITONE (revoke delisting)			
	Tab 15 mg.....	40.00	500	PSM
	Note – PSM tab 15 mg to be delisted from 1 May 2024			
129	PHENOBARBITONE (delisting)			
	Tab 15 mg – 5% DV May-24 to 2026	248.50	500	Noumed Phenobarbitone
	Note – Noumed Phenobarbitone tab 15 mg to be delisted from 1 January 2024			
129	GABAPENTIN (extended HSS expiry date)			
	Note: Gabapentin not to be given in combination with pregabalin			
	Cap 100 mg – 1% DV Feb-22 to 2024 2027	6.45	100	Nupentin
	Cap 300 mg – 1% DV Feb-22 to 2024 2027	8.45	100	Nupentin
	Cap 400 mg – 1% DV Feb-22 to 2024 2027	10.26	100	Nupentin
131	SUMATRIPTAN (extended HSS expiry date)			
	Tab 50 mg – 1% DV Feb-22 to 2024 2027	14.41	90	Sumagran
	Tab 100 mg – 1% DV Feb-22 to 2024 2027	22.68	90	Sumagran

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2024 (continued)

134	ARIPIPRAZOLE (new listing)			
	→ Inj 300 mg vial.....	273.56	1	Abilify Maintena
	→ Inj 400 mg vial.....	341.96	1	Abilify Maintena
	Restricted Initiation			
	<i>Re-assessment required after 12 months</i>			
	Both:			
	1 Patient has a current Special Authority approval for olanzapine depot injection, risperidone depot injection or paliperidone depot injection; and			
	2 Either			
	2.1 Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with olanzapine depot injection, risperidone depot injection or paliperidone depot injection; or			
	2.2 Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been initiated on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection.			
	Continuation			
	<i>Re-assessment required after 12 months</i>			
	The initiation of aripiprazole depot injection has been associated with fewer days of intensive intervention than prior to the initiation of an atypical antipsychotic depot injection.			
142	DEXAMFETAMINE SULFATE (removal of PSS)			
	→ Tab 5 mg – 5% DV Jan-22 to 2024 31-12-23	21.00	100	PSM
142	DEXAMFETAMINE SULFATE (new listing and addition of PSS)			
	→ Tab 5 mg – 5% DV Jun-24 to 2025	29.80	100	Noumed Dexamfetamine
	Note – Aspen and PSM tab 5 mg to be delisted from 1 June 2024			
144	DONEPEZIL HYDROCHLORIDE (new listing and addition of PSS)			
	Tab 5 mg – 5% DV Jun-24 to 2026	3.70	84	Ipca-Donepezil
	Tab 10 mg – 5% DV Jun-24 to 2026	5.50	84	Ipca-Donepezil
	Note – Donepezil-Rex tab 5 mg and 10 mg to be delisted from 1 June 2024			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2024 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

150	GEMCITABINE HYDROCHLORIDE (amended chemical name) Inj 10 mg per ml, 100 ml vial	15.89	1	Gemcitabine Ebewe
150	GEMCITABINE HYDROCHLORIDE (new listing and addition of PSS) Inj 43.3 mg per ml (equivalent to 38 mg per ml gemcitabine), 26.3 ml vial – 5% DV Jun-24 to 2026	18.94	1	DBL Gemcitabine
	Note – Gemcitabine Ebewe inj 10 mg per ml, 100 ml vial to be delisted from 1 June 2024			
159	LAPATINIB (delisting) → Tab 250 mg.....	1,899.00	70	Tykerb
	Note – Tykerb tab 250 mg to be delisted from 1 March 2024			
167	LETROZOLE (new listing) Tab 2.5 mg – 5% DV Jan-22 to 2024	5.84	30	Letrole
	Note – new Pharmacode listing, 2656655			

RESPIRATORY SYSTEM AND ALLERGIES

246	BUDESONIDE († price) Nasal spray 50 mcg per dose	2.89	200 dose	SteroClear
	Nasal spray 100 mcg per dose	3.29	200 dose	SteroClear
251	CAFFEINE CITRATE († price) Oral liq 20 mg per ml (caffeine 10 mg per ml)	16.10	25 ml	Biomed
	Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule	66.40	5	Biomed

VARIOUS

267	SODIUM CHLORIDE († price) Irrigation soln 0.9%, 250 ml bottle.....	21.60	12	Fresenius Kabi
267	WATER († price) Irrigation soln, 250 ml bottle	21.60	12	Fresenius Kabi

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2024 (continued)

VACCINES

295	INFLUENZA VACCINE (amended restriction criteria and delisting) → Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)	11.00	1	Afluria Quad Junior (2023 Formulation)
-----	--	-------	---	---

Initiation—children 6 months to 35 months of age

Children 6 months to 35 months of age (inclusive) from 1 April 2023 to 31 December 2023.

Initiation – cardiovascular disease for patients aged 6 months to 35 months

Any of the following:

- 1 Ischaemic heart disease; or
- 2 Congestive heart failure; or
- 3 Rheumatic heart disease; or
- 4 Congenital heart disease; or
- 5 Cerebrovascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

Initiation – chronic respiratory disease for patients aged 6 months to 35 months

Either:

- 1 Asthma, if on a regular preventative therapy; or
- 2 Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

Initiation – Other conditions for patients aged 6 months to 35 months

Any of the following:

- 1 Diabetes; or
- 2 Chronic renal disease; or
- 3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
- 4 Autoimmune disease; or
- 5 Immune suppression or immune deficiency; or
- 6 HIV; or
- 7 Transplant recipient; or
- 8 Neuromuscular and CNS diseases/ disorders; or
- 9 Haemoglobinopathies; or
- 10 Is a child on long term aspirin; or
- 11 Has a cochlear implant; or
- 12 Errors of metabolism at risk of major metabolic decompensation; or
- 13 Pre and post splenectomy; or
- 14 Down syndrome; or
- 15 Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness.

Note – Afluria Quad Junior (2023 Formulation) inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) to be delisted from 1 February 2024

295	INFLUENZA VACCINE (amended restriction criteria – amended criteria shown only and delisting) → Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	110.00	10	Afluria Quad (2023 Formulation)
-----	--	--------	----	------------------------------------

Initiation – People over 65

The patient is 65 years of age or over.

Initiation – People of Māori or any Pacific ethnicity

People 55 to 64 years of age (inclusive) and is Māori or of any Pacific ethnicity, from 1 April 2023 to 31 December 2023.

continued...

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 January 2024 (continued)

continued...

Initiation – cardiovascular disease for patients 3 years and over

Any of the following:

- 1 Ischaemic heart disease; or
- 2 Congestive heart failure; or
- 3 Rheumatic heart disease; or
- 4 Congenital heart disease; or
- 5 Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

Initiation – chronic respiratory disease for patients 3 years and over

Either:

- 1 Asthma, if on a regular preventative therapy; or
- 2 Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

Initiation – Other conditions for patients 3 years and over

Either:

- 1 Any of the following:
 - 1.1 Diabetes; or
 - 1.2 chronic renal disease; or
 - 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
 - 1.4 Autoimmune disease; or
 - 1.5 Immune suppression or immune deficiency; or
 - 1.6 HIV; or
 - 1.7 Transplant recipient; or
 - 1.8 Neuromuscular and CNS diseases/ disorders; or
 - 1.9 Haemoglobinopathies; or
 - 1.10 Is a child on long term aspirin; or
 - 1.11 Has a cochlear implant; or
 - 1.12 Errors of metabolism at risk of major metabolic decompensation; or
 - 1.13 Pre and post splenectomy; or
 - 1.14 Down syndrome; or
 - 1.15 Is pregnant; or
 - 1.16 Is a child 3 to 4 years of age (inclusive) who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a Public Hospital.

Initiation – Serious mental health conditions or addiction

Any of the following:

- 1 schizophrenia; or
- 2 major depressive disorder; or
- 3 bipolar disorder; or
- 4 schizoaffective disorder; or
- 5 person is currently accessing secondary or tertiary mental health and addiction services.

Initiation – children from 3 to 12 years of age (inclusive)

Children 3 to 12 years of age (inclusive) from 1 April 2023 to 31 December 2023.

Note – Afluria Quad (2023 Formulation) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) to be delisted from 1 February 2024

Index

Pharmaceuticals and brands

A	
ABACAVIR SULPHATE	8
Ability Maintena	10
Afluria Quad (2023 Formulation)	12
Afluria Quad Junior (2023 Formulation)	12
ALLOPURINOL	8
AMILORIDE HYDROCHLORIDE	7
ARIPIRAZOLE	10
ASPIRIN	6
B	
BUDESONIDE	11
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL	9
C	
CAFFEINE CITRATE	11
Cardizem CD	7
CHLOROTHIAZIDE	7
CLARITHROMYCIN	8
COLECALCIFEROL	6
D	
DBL Gemcitabine	11
DEXAMETHASONE	8
DEXAMFETAMINE SULFATE	10
DEXTROSE	6
DILTIAZEM HYDROCHLORIDE	7
DONEPEZIL HYDROCHLORIDE	10
DP Lotn HC	7
Drofate	7
E	
EPHEDRINE	7
Ephedrine Juno	7
Estradot	8
Ethics Aspirin EC	6
EVARA White Soft Paraffin	7
F	
FEBUXOSTAT	8
Febuxostat (Teva)	8
FENTANYL	9
FOLIC ACID	6
Folic Acid Viatris	6
G	
GABAPENTIN	9
GEMCITABINE	11
Gemcitabine Ebewe	11
GEMCITABINE HYDROCHLORIDE	11
GLUCOSE [DEXTROSE]	6
H	
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN	7
I	
INFLUENZA VACCINE	12
Inresa	6
Ipca-Allopurinol	8
Ipca-Donpezil	10
IPCA-Metoprolol	7
IPCA-Propranolol	7
K	
KETAMINE	9
Klacid	8
L	
LAPATINIB	11
Letrole	11
LETROZOLE	11
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE	9
LIGNOCAINE	9
M	
MAGNESIUM SULPHATE	6
MEROPENEM	8
Meropenem-AFT	8
METFORMIN HYDROCHLORIDE	6
Metformin Viatris	6
METOPROLOL TARTRATE	7
Mylan (24 hr release)	7
N	
NIFEDIPINE	7
Noumed Dexamfetamine	10
Noumed Phenobarbitone	9
Nupentin	9
O	
OESTRADIOL	8
P	
PARAFFIN	7
Pegasys	8
PEGYLATED INTERFERON ALFA-2A	8
PHENOBARBITONE	9
POTASSIUM CITRATE	7
PROPRANOLOL	7
S	
SODIUM ACID PHOSPHATE	6
SODIUM BICARBONATE	6
SODIUM CHLORIDE	6, 11
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]	6
SPIRONOLACTONE	7
SteroClear	11
SUCROSE	9
Sumagran	9

Index

Pharmaceuticals and brands

SUMATRIPTAN	9	V	
T		Vit.D3	6
TERIPARATIDE	8	W	
Teriparatide - Teva	8	WATER	11
Topicaline	9	Z	
Tykerb	11	Ziagen	8

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

